Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 30;7:78. doi: 10.3389/fcvm.2020.00078

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Wang, Zhang and Zhang.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Possible algorithm regarding the selection of anti-inflammatory therapy for COVID-19 patients with cardiovascular impairment. *Severe cases refer to patients with the following conditions according to the 6th version of the Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia: respiratory rate≥30 bpm; SpO2 ≤ 30% at rest; PaO2/FiO2 ≤ 300 mmHg; progression on chest images>50% within 24 to 48 h; respiratory failure that requires mechanical ventilation; shock; organ dysfunction that requires ICU admission. ^†Response refers to the response to anti-inflammatory therapy. The criteria include but are not limited to decreased white blood cell counts, decreased hsCRP levels, decreased cytokine levels, significant symptom improvement, and significant improvement in chest images. Residual inflammation refers to evidence of a persistent state of high inflammation characterized by high levels of hsCRP and/or serum cytokines.